Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Tasly Pharmaceutical Group Co., Ltd
  6. News
  7. Summary
    600535   CNE000001C81

TASLY PHARMACEUTICAL GROUP CO., LTD

(600535)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-09-29
9.760 CNY   +0.62%
09/30Tasly Pharmaceutical Wins Nod For Clinical Trial of Psoriasis Drug
MT
08/19Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/19Tasly Pharmaceutical Group Scraps Plan to Spin Off BioPharm Unit for Listing
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021

03/30/2022 | 04:37am EDT

Tasly Pharmaceutical Group Co., Ltd reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 7,898.1 million compared to CNY 13,505.3 million a year ago. Revenue was CNY 7,951.96 million compared to CNY 13,576.11 million a year ago.

Net income was CNY 2,358.86 million compared to CNY 1,125.89 million a year ago. Basic earnings per share from continuing operations was CNY 1.57 compared to CNY 0.75 a year ago. Diluted earnings per share from continuing operations was CNY 1.57 compared to CNY 0.75 a year ago.


© S&P Capital IQ 2022
All news about TASLY PHARMACEUTICAL GROUP CO., LTD
09/30Tasly Pharmaceutical Wins Nod For Clinical Trial of Psoriasis Drug
MT
08/19Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended Ju..
CI
08/19Tasly Pharmaceutical Group Scraps Plan to Spin Off BioPharm Unit for Listing
CI
07/12Transcript : Mauna Kea Technologies SA, Tasly Pharmaceutical Group Co., Ltd -..
CI
07/11Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing A..
CI
04/25Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ende..
CI
03/30Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended De..
CI
01/05Tranche Update on Tasly Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced o..
CI
2021Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended ..
CI
2021Tranche Update on Tasly Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced o..
CI
More news
Financials
Sales 2022 8 321 M 1 170 M 1 170 M
Net income 2022 512 M 72,0 M 72,0 M
Net cash 2022 561 M 78,9 M 78,9 M
P/E ratio 2022 28,7x
Yield 2022 2,02%
Capitalization 14 502 M 2 039 M 2 039 M
EV / Sales 2022 1,68x
EV / Sales 2023 1,54x
Nbr of Employees 9 437
Free-Float 50,8%
Chart TASLY PHARMACEUTICAL GROUP CO., LTD
Duration : Period :
Tasly Pharmaceutical Group Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TASLY PHARMACEUTICAL GROUP CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 9,76 CNY
Average target price 10,96 CNY
Spread / Average Target 12,3%
EPS Revisions
Managers and Directors
Jing Su Director
Jie Wei Chief Financial Officer
Kai Jing Yan Chairman
Zheng Liang Ye Chairman-Supervisory Board
Ai Jian Wang Independent Director